Zachary Bessette

GU Oncology Now

Researchers reported <a href="https://www.auajournals.org/doi/10.1097/JU.0000000000003240.10" target="_blank" rel="noopener">long-term exploratory analyses</a> of subgroups defined by response to first-line chemotherapy in the phase 3 JAVELIN Bladder 100 trial.Results were presented at the American Urology Association 2023 Annual Meeting.JAVELIN Bladder 100 showed first-line avelumab maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) compared with BSC alone in patients with advanced urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy.Bego&ntilde;a Valderrama, MD, and colleagues conducted exploratory analyses based on response to first-line chemotherapy (complete response [CR], partial response [PR], or stable disease [SD]) after at least 2 years of follow-up, as well as visceral versus nonvisceral disease at chemotherapy initiation.At data cutoff, median follow-up in both treatment arms (avelumab plus BSC or BSC alone) was &ge;38 months. Researchers reported prolonged OS and progression-free survival in the avelumab-plus-BSC arm in all subgroups.Additionally, they noted that subsequent second-line anticancer drug therapy was received in all subgroups (CR subgroup, 50.0% vs 74.2%, respectively; PR subgroup, 58.3% vs 71.8%; SD subgroup, 46.4% vs 70.4%).Long-term safety was consistent across subgroups, they added.&ldquo;These findings further support avelumab first-line maintenance as standard of care for all patients with advanced urothelial carcinoma who have not progressed with first-line platinum-based chemotherapy,&rdquo; Dr. Valderrama and colleagues concluded.

First-line Avelumab Maintenance for Advanced UC: Long-term Results of JAVELIN Bladder 100

AUA 2023: Focus on Bladder Cancer

Researchers reported long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the phase 3 JAVELIN Bladder 100 trial.

JAVELIN Bladder 100 Long-term Results: Avelumab Maintenance

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe